U
ALXA

UBS’s Alexza Pharmaceuticals Inc ALXA Stock Holding History

UBS’s Portfolio ALXA Stock Details ALXA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-500
Closed -$2K – 10994
2013
Q2 		$2K Buy
+500
New +$2.27K ﹤0.01% 9907

Other funds holding ALXA

LPA
Lansdowne Partners Austria Vienna, Austria $29M AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
CLOS
Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $8.13B AUM 26.03% 1-Year Est. Return
FAM
Fortaleza Asset Management Chicago, Illinois $12.3M AUM 48.33% 1-Year Est. Return
HHMI
Howard Hughes Medical Institute Chevy Chase, Maryland $416M AUM 13.82% 1-Year Est. Return

UBS's ALXA Position: Q3 2014 in Review

UBS reduced its Alexza Pharmaceuticals Inc (ALXA) stake by 64% in Q3 2014, selling an estimated $18.1K and leaving 2,620 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #9375.

UBS first reported a position in ALXA in Q2 2013 and has held it in 6 quarters since. The position peaked at $131K in Q2 2013. 38 funds tracked by Wall St. Rank hold ALXA as of Q3 2014.

  • UBS held 2,620 shares of Alexza Pharmaceuticals Inc worth $6K as of Q3 2014.
  • UBS sold 4,740 Alexza Pharmaceuticals Inc shares in Q3 2014, an estimated $18.1K.
  • Alexza Pharmaceuticals Inc made up ﹤0.01% of UBS's portfolio in Q3 2014, its #9375 holding.
  • UBS first reported a position in Alexza Pharmaceuticals Inc in Q2 2013 and has held it in 6 quarters since.
  • UBS's Alexza Pharmaceuticals Inc position peaked at $131K in Q2 2013.
  • 38 funds tracked by Wall St. Rank held Alexza Pharmaceuticals Inc as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.